全文获取类型
收费全文 | 58926篇 |
免费 | 6008篇 |
国内免费 | 118篇 |
专业分类
耳鼻咽喉 | 770篇 |
儿科学 | 1728篇 |
妇产科学 | 1360篇 |
基础医学 | 8734篇 |
口腔科学 | 1245篇 |
临床医学 | 7206篇 |
内科学 | 11195篇 |
皮肤病学 | 786篇 |
神经病学 | 5868篇 |
特种医学 | 2229篇 |
外国民族医学 | 58篇 |
外科学 | 7515篇 |
综合类 | 1210篇 |
现状与发展 | 1篇 |
一般理论 | 55篇 |
预防医学 | 6003篇 |
眼科学 | 1400篇 |
药学 | 4208篇 |
中国医学 | 61篇 |
肿瘤学 | 3420篇 |
出版年
2021年 | 740篇 |
2020年 | 542篇 |
2019年 | 831篇 |
2018年 | 917篇 |
2017年 | 703篇 |
2016年 | 816篇 |
2015年 | 859篇 |
2014年 | 1284篇 |
2013年 | 2039篇 |
2012年 | 2687篇 |
2011年 | 2803篇 |
2010年 | 1684篇 |
2009年 | 1427篇 |
2008年 | 2634篇 |
2007年 | 2647篇 |
2006年 | 2676篇 |
2005年 | 2695篇 |
2004年 | 2577篇 |
2003年 | 2331篇 |
2002年 | 2252篇 |
2001年 | 1803篇 |
2000年 | 1911篇 |
1999年 | 1613篇 |
1998年 | 704篇 |
1997年 | 594篇 |
1996年 | 520篇 |
1995年 | 584篇 |
1994年 | 556篇 |
1993年 | 509篇 |
1992年 | 1248篇 |
1991年 | 1294篇 |
1990年 | 1211篇 |
1989年 | 1170篇 |
1988年 | 1160篇 |
1987年 | 1034篇 |
1986年 | 1018篇 |
1985年 | 962篇 |
1984年 | 811篇 |
1983年 | 710篇 |
1982年 | 506篇 |
1981年 | 506篇 |
1980年 | 472篇 |
1979年 | 800篇 |
1978年 | 626篇 |
1977年 | 558篇 |
1976年 | 510篇 |
1975年 | 461篇 |
1974年 | 565篇 |
1973年 | 529篇 |
1972年 | 458篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Cody M. Lebeck Lee MD Ioannis A. Ziogas MD Rajiv Agarwal MD Sophoclis P. Alexopoulos MD Kristen K. Ciombor MD Lea K. Matsuoka MD Daniel B. Brown MD Cathy Eng MD 《Cancer》2022,128(12):2243-2257
The 5-year overall survival rate of a patient with unresectable metastatic colorectal cancer is poor at approximately 14%. Similarly, historical data on liver transplantation (LT) in those with colorectal liver metastases (CRLM) showed poor outcomes, with 5-year survival rates between 12% and 21%. More recently, limited data have shown improved outcomes in select patients with 5-year overall survival rates of approximately 60%. Despite these reported survival improvements, there is no significant improvement in disease-free survival. Given the uncertain benefit with this therapeutic approach and a renewed investigational interest, we aimed to conduct a contemporary systematic review on LT for CRLM. A systematic review of the literature was performed according to the preferred reporting items for systematic reviews and meta-analysis statement. English articles reporting on data regarding LT for CRLM were identified through the MEDLINE (via PubMed), Cochrane Library, and ClinicalTrials.gov databases (last search date: December 16th, 2021) by 2 researchers independently. A total of 58 studies (45 published and 13 ongoing) were included. Although early retrospective studies suggest the possibility that some carefully selected patients may benefit from LT, there is minimal prospective data on the topic and LT remains exploratory in the setting of CRLM. Additionally, several other challenges, such as the limited availability of deceased donor organs and defining appropriate selection criteria, remain when considering the implementation of LT for these patients. Further evidence from ongoing prospective trials is needed to determine if and to what extent there is a role for LT in patients with surgically unresectable CRLM. 相似文献
2.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
3.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
4.
5.
6.
7.
8.
Benedict M Devereaux Andrew C F Taylor Eugene Athan David J Wallis Robyn R Brown Sue M Greig Fiona K Bailey Karen Vickery Elizabeth Wardle Dianne M Jones 《Journal of gastroenterology and hepatology》2019,34(12):2086-2089
Concern has been raised regarding the use of simethicone, a de‐foaming agent, during endoscopic procedures. Following reports of simethicone residue in endoscope channels despite high level disinfection, an endoscope manufacturer recommended that it not be used due to concerns of biofilm formation and a possible increased risk of microorganism transmission. However, a detailed mucosal assessment is essential in performing high‐standard endoscopic procedures. This is impaired by bubbles within the gastrointestinal lumen. The Gastroenterological Society of Australia's Infection Control in Endoscopy Guidelines (ICEG) Committee conducted a literature search utilizing the MEDLINE database. Further references were sourced from published paper bibliographies. Following a review of the available evidence, and drawing on extensive clinical experience, the multidisciplinary ICEG committee considered the risks and benefits of simethicone use in formulating four recommendations. Published reports have documented residual liquid or crystalline simethicone in endoscope channels after high level disinfection. There are no data confirming that simethicone can be cleared from channels by brushing. Multiple series report benefits of simethicone use during gastroscopy and colonoscopy in improving mucosal assessment, adenoma detection rate, and reducing procedure time. There are no published reports of adverse events related specifically to the use of simethicone, delivered either orally or via any endoscope channel. An assessment of the risks and benefits supports the continued use of simethicone during endoscopic procedures. Strict adherence to instrument reprocessing protocols is essential. 相似文献
9.
10.